At the same time AbbVie is able to dictate to smaller-cap biotech stocks and one such partner is Galapagos.
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion. That would be a YoY (year-over-year) growth of around 18.0%. The growth rate is calculated by using the midpoint of the revenue guidance range for 2016 and 2017.
Last week, then-President-Elect Trump rattled biotechs when, during a press conference, he expressed frustration with Medicare Part D's prohibition against negotiating drug prices.
The healthcare sector has long been a victim of concerns over increased regulatory scrutiny related to high drug prices. While the worries cooled down after Trump’s victory, the biotech and pharma stocks were again troubled by the President’s non-friendly plan to lower drug prices (read: Trump Attacks Biotech & Pharma: ETFs Bleed). Further, Trump signed an executive order to repeal and replace the Affordable Care Act, which covers some 20 million Americans, soon after he takes office.
President Donald Trump’s warning to the pharmaceutical industry over exorbitant drug pricing did irk investors, but, his business tax plans and intentions to “repeal and replace” the Obamacare should be a boon for healthcare companies.
Some of the most expensive drugs on the market are used to treat cancer, and those drugs are getting increasingly costlier as they get more complex. Over the past five years, IMS Health reports that 70 new cancer drugs have been launched, and while their prices vary, the vast majority of them cost upwards of $100,000 per year. Because cancer drug prices are soaring, IMS Health thinks global spending on cancer drugs could climb from $100 billion in 2014 to $150 billion in 2020.
While the run since the Trump election and now the inauguration has been solid, there are some storm clouds on the horizon. Volatility has drifted to historic lows, while price-to-earnings on a current and forward basis are at highs not seen in years. With yields still low, bonds are really not a place to put money, so what do equity investors do now? One Wall Street firm we cover thinks that cheap stocks may be a smart move now.
After a massive price ramp-up, Gilead Sciences (NASDAQ:GILD) hit the skids through most of 2015 and 2016 as its hepatitis C, or HCV, portfolio reported falling sales. And it's hard to blame the market for its critical reaction: In its third-quarter earnings, Gilead reported that HCV revenue had plummeted by a shocking 31% year over year.
LOS ANGELES, CA / ACCESSWIRE / January 23, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the "Class Period"), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.
On Friday, Donald Trump was sworn in as the new U.S. President and gave a protectionist speech, which in turn had a broad-based positive impact on U.S. benchmarks. In his speech, Trump focused on America’s prosperity and strength and pledged to make “America great again.” All three key indexes rallied with the Dow snapping a five-session losing stretch. However, the major indexes registered weekly losses as investors looked for more clarity on Trump’s economic policies.
Bret Jensen is one of 25 Seeking Alpha Contributors participating in the 2017 DIY Investing Summit. In the summit, two of the questions I asked Bret: what his "State of the Markets" address to DIY investor would be and how is he positioning himself for 2017. Below is an excerpt from the interview and a summary of his response.
* ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corporation and become a vertically integrated commercial plasma products company
SAN FRANCISCO, CA--(Marketwired - January 23, 2017) - Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Ahead of today's trading session, Stock-Callers.com draws investors' attention to four Biotech equities to see how they have fared at the close: Kite Pharma Inc. (NASDAQ: KITE), BioPharmX Corp. (NYSEMKT: BPMX), OvaScience Inc. (NASDAQ: OVAS), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). According to a report on the NASDAQ, Biotechnology shares were relative laggards on Friday, January 20th, 2017, down on the day by about 0.
Watching Donald Trump take the oath of office on Friday, I felt like I was living one of those surreal alternative history movies.
Change is on its way in Washington, D.C. And the possible impacts for a big biotech like Gilead Sciences (NASDAQ:GILD) could be substantial. How might Gilead fare under four to eight years of President Trump?
While investors often do pay a premium price for stocks that boast high dividend yields, that's not always the case. In fact, three healthcare stocks with attractive yields are incredibly cheap right now. If you're looking for bargain dividend stocks, here's why you'll definitely want to consider AbbVie (NYSE:ABBV), Gilead Sciences (NASDAQ:GILD), and Teva Pharmaceutical (NYSE:TEVA).
A lot of the discussion related to curbing runaway drug prices in the United States has focused on the importation of drugs from neighboring Canada. But are drugs really less expensive there? Often, the answer is yes. For instance, here are five common medicines that are much cheaper to buy in Canada than in the United States.
SAN DIEGO, Jan. 21, 2017 /PRNewswire/ -- Johnson & Weaver, LLP announces that a class action complaint was filed on behalf of purchasers of Seattle Genetics, Inc., (NASDAQ: SGEN) securities during the period between October 27, 2016, and December 23, 2016, inclusive (the "Class Period"). Seattle Genetics, a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide.
Data for Phase 2b study of lead drug Aramchol in 240 NASH patients due in second quarter of 2018.
Voyager Therapeutics (NASDAQ:VYGR) announces updates regarding the Phase 1b study of VY-AADC01 for patients with advanced Parkinson’s disease.
Pluristem Therapeutics (NASDAQ:PSTI) amends its underwriting agreement with H.C. Wainwright to increase its "bought deal" offering to $15M. Under the bought deal arrangement, Wainwright will purchase the entire offering of 12,244,898 common shares at $1.225. It will also receive warrants to purchase up to 7,346,939 common shares at $1.40. Gross proceeds will be $15M.
The European Medicines Agency (EMA) accepts for review Gilead Sciences' (NASDAQ:GILD) Marketing Authorization Application (MAA) seeking approval of its once-daily single-table regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV) infection. The MAA has accelerated review status which shortens the review clock to 150 days from the usual 210 days.
LOS ANGELES, CA / ACCESSWIRE / January 20, 2017 / Lundin Law PC, a shareholder rights firm announces a class action lawsuit against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.